MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Начало・Списък с акции・Krystal Biotech Inc

Krystal Biotech Inc

Затворен

СекторЗдравеопазване

264.06 -1.49

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

260.77

Максимум

266.87

Ключови измерители
By Trading Economics
Приходи	-28M 51M
Продажби	9.3M 107M
P/E Средно за сектора	39.038 63.808
Марж на печалбата	47.99
Служители	295
EBITDA	-10M 40M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+22.26% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-145M 7.9B
Предишно отваряне	265.55
Предишно затваряне	264.06

Настроения в новините

By Acuity

50%

167 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

133.221 / 169.73 Подкрепа & съпротива

Krystal Biotech Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.04.2026 г., 23:14 ч. UTC

Печалби

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15.04.2026 г., 23:14 ч. UTC

Печалби

Battery Maker CATL First Quarter Net Rose On Strong Demand

15.04.2026 г., 17:13 ч. UTC

Значими двигатели на пазара

Tesla Shares Rise on Completion of AI5 Chip Design Process

15.04.2026 г., 23:39 ч. UTC

Пазарно говорене

Nikkei May Rise After Gains on Wall Street -- Market Talk

15.04.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15.04.2026 г., 22:41 ч. UTC

Печалби

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15.04.2026 г., 22:38 ч. UTC

Печалби

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15.04.2026 г., 22:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.04.2026 г., 22:15 ч. UTC

Пазарно говорене

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15.04.2026 г., 22:14 ч. UTC

Печалби

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15.04.2026 г., 22:12 ч. UTC

Печалби

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15.04.2026 г., 22:11 ч. UTC

Печалби

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15.04.2026 г., 22:11 ч. UTC

Печалби

Lens Technology Swings to Loss in 1Q>300433.SZ

15.04.2026 г., 22:07 ч. UTC

Печалби

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15.04.2026 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15.04.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

15.04.2026 г., 20:30 ч. UTC

Печалби

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

15.04.2026 г., 20:06 ч. UTC

Пазарно говорене

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15.04.2026 г., 19:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15.04.2026 г., 19:25 ч. UTC

Пазарно говорене

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15.04.2026 г., 19:00 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15.04.2026 г., 18:58 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15.04.2026 г., 18:11 ч. UTC

Придобивния, сливания и поглъщания

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15.04.2026 г., 17:45 ч. UTC

Придобивния, сливания и поглъщания

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15.04.2026 г., 16:58 ч. UTC

Печалби

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15.04.2026 г., 16:52 ч. UTC

Печалби

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15.04.2026 г., 16:46 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15.04.2026 г., 16:37 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Krystal Biotech Inc Прогноза

Ценова цел

By TipRanks

22.26% нагоре

12-месечна прогноза

Среден 328.33 USD 22.26%

Висок 371 USD

Нисък 284 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Krystal Biotech Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Krystal Biotech Inc през последните 3 месеца.

Техническа оценка

By Trading Central

133.221 / 169.73Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

167 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.